OncoMatch/Clinical Trials/NCT05188508
Pembrolizumab, Olaparib, and Temozolomide for People With Glioma
Is NCT05188508 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Pembrolizumab and Olaparib and Temozolomide for glioma.
Treatment: Pembrolizumab · Olaparib and Temozolomide — This study will test the safety and effectiveness of a combination of pembrolizumab, olaparib, and temozolomide to see how well these drugs work when given together in people with a glioma that either did not respond to previous treatment or came back after treatment.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Other
Cancer type
Glioblastoma
Biomarker criteria
Required: ATM deleterious mutation
Required: BARD1 deleterious mutation
Required: BRCA1 deleterious mutation
Required: BRCA2 deleterious mutation
Required: BRIP1 deleterious mutation
Required: CDK12 deleterious mutation
Required: CDKN2A wild-type
Required: CDKN2B wild-type
Required: CHEK1 deleterious mutation
Required: CHEK2 deleterious mutation
Required: FANCL deleterious mutation
Required: IDH1 mutation
Required: IDH1 wild-type
Required: PALB2 deleterious mutation
Required: PPP2R2A deleterious mutation
Required: RAD51B deleterious mutation
Required: RAD51C deleterious mutation
Required: RAD51D deleterious mutation
Required: RAD54L deleterious mutation
Disease stage
Required: Stage II, III
Grade: iiiii
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: surgical resection
Cannot have received: any investigational or standard anti-tumor therapy
Lab requirements
Blood counts
absolute neutrophil count (anc) ≥1500/μl platelets ≥100 000/μl hemoglobin ≥9.0 g/dl or ≥5.6 mmol/l
Kidney function
creatinine or measured or calculated creatinine clearance (gfr can also be used in place of creatinine or crcl) ≤1.5 × uln or ≥30 ml/min for participant with creatinine levels <1.5 × institutional uln
Liver function
total bilirubin ≤1.5 ×uln or direct bilirubin ≤uln for participants with total bilirubin levels >1.5 × uln ast (sgot) and alt (sgpt) ≤2.5 × uln (≤5 × uln for participants with liver metastases)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Hartford Healthcare Alliance (Data Collection Only) · Hartford, Connecticut
- BAPTIST ALLIANCE - MCI (Data Collection Only) · Miami, Florida
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) · Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) · Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) · Montvale, New Jersey
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05188508 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior any investigational or standard anti-tumor therapy disqualifies patients from enrollment.
Does this trial require ATM?
Yes, ATM deleterious mutation is a required biomarker for enrollment.
Does this trial require BARD1?
Yes, BARD1 deleterious mutation is a required biomarker for enrollment.
Does this trial require BRCA1?
Yes, BRCA1 deleterious mutation is a required biomarker for enrollment.
What disease stage is eligible?
Stage II or III is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages